---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Incidence"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Incidence. Topics: Annual incidence of diagnosed HAE type 1 and 2: Finnish national register; Incidence of treated HAE: Swedish National Prescribed Drug Register, 2024; Incidence across ethnic groups. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/incidence"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Hereditary angioedema

<a id="topic-2.2.1.2.1-1"></a>

### Annual incidence of diagnosed HAE type 1 and 2: Finnish national register

> “In Finland, 103 new patients were diagnosed with HAE-1/2 within the 10-year study period.”
> “The mean incidence of HAE-1/2 was 0.16/100,000, showing an annual variability between 0.07 and 0.22/100,000 (4 to 12 new cases annually)”
> “In our study the incidence seemed quite stable, especially considering that HAE is a rare disease, and a few new patients (e.g. a new HAE family) have a big impact on the calculated annual incidence in a small country like Finland.”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

<a id="topic-2.2.1.2.1-2"></a>

### Incidence of treated HAE: Swedish National Prescribed Drug Register, 2024

> “The total number of patients treated for HAE has increased from 188 to 245 patients between 2021 and 2024.”
> “This corresponds to a prevalence and incidence rate of 2.31/100,000 and 0.36/100,000 in 2024, respectively.”
> “The observed prevalence aligns with prior estimates, though the incidence, when measured as number of new patients treated for HAE, is higher than what has been observed elsewhere.”

Source: [Danielsson et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-2-2/current-use-of-hereditary-angioedema-hae-treatments-in-sweden-an-analysis-of-the-national-prescribed-drug-register)

<a id="topic-2.2.1.2.1-3"></a>

### Incidence across ethnic groups

> “No significant differences in the incidence of C1-INH deficiency across ethnic groups have been confirmed.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
